TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
1.994
+0.004 (0.18%)
Mar 26, 2026, 12:52 PM EDT - Market open
TuHURA Biosciences Employees
TuHURA Biosciences had 19 employees as of December 31, 2024. The number of employees increased by 18 or 1,800.00% compared to the previous year.
Employees
19
Change (1Y)
18
Growth (1Y)
1,800.00%
Revenue / Employee
n/a
Profits / Employee
-$1,541,833
Market Cap
102.19M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 19 | 18 | 1,800.00% |
| Dec 31, 2023 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Inovio Pharmaceuticals | 112 |
| Rani Therapeutics Holdings | 106 |
| Oncolytics Biotech | 28 |
| Cognition Therapeutics | 28 |
| Q32 Bio | 24 |
| Genelux | 24 |
| Reviva Pharmaceuticals Holdings | 14 |
HURA News
- 3 days ago - Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers - PRNewsWire
- 27 days ago - TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
- 4 weeks ago - TuHURA Biosciences Announces Participation in Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers - PRNewsWire
- 6 weeks ago - TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - PRNewsWire
- 7 weeks ago - TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma - PRNewsWire
- 3 months ago - TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone - PRNewsWire
- 3 months ago - TuHURA Biosciences Provides Corporate Update Following Recent Financing - PRNewsWire